Apobiologix's Bambevi (biosimilar- bevacizumab) Receives Health Canada Approval for Multiple Cancer Indications
Shots:
- Apobiologix expands its footprints in Canada with the approval of Bambevi + CT to treat colorectal- lung- brain and ovarian cancer
- The approval is coupled with well-established Apobiologix supportive care products that enable the company to transform access to affordable therapies in oncology and other indications
- In 2016- Apobiologix launched its first product- Grastofil (filgrastim) followed by the launch of Lapelga in 2019 in Canada. Additionally- Apobiologix is the first company to offer a portfolio of G-CSF biosimilars
| Ref: Newswire | Image: Biospace
Click here to read the full press release
Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com
